Effects of Faricimab on kidney function in diabetic patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates how the intravitreal injection of Faricimab, an anti-VEGF drug, affects the renal function of diabetic patients. It will enroll 60 participants, with half receiving Faricimab and the other half receiving Aflibercept. Key assessments will include laboratory tests for renal function and glycemic control, as well as visual acuity and retinal imaging at baseline, 6 months, and 12 months. The goal is to determine if Faricimab has a different impact on kidney function compared to traditional treatments.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with diabetes
* Patients with DME or nAMD or macular edema secondary to retinal vein occlusion
* Patients already receiving nephroprotective drugs

Exclusion Criteria:

* Patients with end stage renal disease
* Pregnancy
* Patients with other retinal disorders
* Previous renal transplantation Patients under hemodialysis

Where it's running

• University Hospital of Alexandroupolis
  Alexandroupoli, Evros, Greece Recruiting
• University Hospital of Alexandroupolis
  Alexandroupoli, Greece Completed

Study contacts

• Study coordinator: Asli Perente, Dr
• Email: asli_perende-90@hotmail.com
• Phone: +306951577205

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Early imaging changes with faricimab versus biosimilar ranibizumab for diabetic retinal disease

  This trial will see if faricimab or a biosimilar ranibizumab causes different early OCT and OCTA imaging changes in adults with diabetic retinopathy or diabetic macular edema who need anti-VEGF injections.

  Recruiting Osijek University Hospital · Osijek · NCT07520045

• Oral N-Acetylcysteine for Diabetic Macular Edema

  This study tests whether taking N-acetylcysteine by mouth can help people with center-involving diabetic macular edema who don’t yet need anti-VEGF therapy.

  Recruiting Phase 2 Tanta University · Damietta · NCT07917338

• 4D-150 gene therapy injected into the eye for adults with diabetic macular edema

  This study tests whether a one-time intravitreal injection of 4D-150 can help adults with diabetic macular edema compare to aflibercept.

  Recruiting at 23 sites Phase 3 4D Molecular Therapeutics · Scottsdale, Arizona and 93 other locations · NCT07867080

• Corticosteroid for Diabetic Macular Edema (DME) in Adults with Diabetic Retinopathy

  This trial tests whether intravitreal corticosteroid injections can influence inflammatory biomarkers and improve DME in adults with type 2 diabetes.

  Recruiting Phase 4 Vanderbilt University Medical Center · Nashville, Tennessee · NCT07843849

• Oral BGE-102 for center-involved diabetic macular edema (Phase 2)

  This trial tests whether taking BGE-102 by mouth, alone or with an anti-VEGF drug, can help preserve or improve vision in adults with center-involved diabetic macular edema.

  Recruiting at 16 sites Phase 2 BioAge Labs, Inc. · Bakersfield, California and 15 other locations · NCT07812090

• Tabirafusp Tedromer vs Aflibercept for Diabetic Macular Edema (DME)

  This study tests whether Tabirafusp Tedromer can work as well as or better than Aflibercept to help people with Diabetic Macular Edema.

  Recruiting at 52 sites Phase 3 Kodiak Sciences Inc · Scottsdale, Arizona and 51 other locations · NCT07734844

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.